Patrys Ltd (ASX:PAB) CEO Dr James Campbell speaks with Andrew Scott from Proactive about new preclinical data for its full-sized IgG antibody, PAT-DX3 showing that it can cross the blood-brain barrier in healthy animals. “These properties open up a range of applications for using deoxymabs to deliver small molecule therapeutics and gene editing technologies directed to various neurological targets and conditions," said Dr Campbell.
Patrys' preclinical data demonstrates PAT-DX3 can cross blood-brain barrier
